outta the blue, some big gains on CXSPY today. It is actually...

outta the blue, some big gains on CXSPY today.

It is actually overpriced in the US right now given the 15:1 ratio to CXS.

I doubt they will find a Euro partner by the end of this quarter. And since the FDA NDA was a couple months late, I expect the EMEA sumbittal to be late as well.

Still a great buy for the next 9-12 months, however.